title: Effect of topical 0.03% flurbiprofen and 0.005% latanoprost, alone and in combination, on normal canine eyes.
abstract: OBJECTIVE
  Evaluate the influence of topically applied flurbiprofen 0.03% and latanoprost 0.005%, alone or in combination, in normal canines.
  
  
  METHODS
  10 Normal Beagles.
  
  
  METHODS
  Intraocular pressure (IOP), pupil size, aqueous flare, conjunctival hyperemia, and blepharospasm were evaluated bilaterally five times daily (8 am, 11 am, 2 pm, 5 pm, and 8 pm). The study consisted of a training and acclimation period, followed by 3, 1-week experiment periods. A 2-week washout period occurred between each experiment period. During period 1, all dogs received flurbiprofen (three doses 6-h apart) in the treated eye, whereas in period 2, all dogs received latanoprost (one dose 24-h apart). During period 3, both latanoprost (one dose 24-h apart) and flurbiprofen (three doses 6-h apart) were administered in the treated eye.
  
  
  RESULTS
  Flurbiprofen resulted in a mean IOP elevation of 1.1 mmHg (8.65%) in the treated eye, as compared with the control eye. No effect on pupil size, conjunctival hyperemia, or aqueous flare was noted. Latanoprost resulted in a mean IOP reduction of 3.4 mmHg (30.19%). Combined latanoprost and flurbiprofen resulted in a mean IOP reduction of 2.7 mmHg (24.56%). Miosis was noted in the treated eyes during both latanoprost periods, with maximal pupil constriction 3-h post-dose. This was followed by relative mydriasis 24-h post-dose, persisting 48 h after the last dose. The degree of conjunctival hyperemia varied between individuals. Neither blepharospasm nor aqueous flare was noted at any time point.
  
  
  CONCLUSIONS
  Concurrent administration of latanoprost and flurbiprofen resulted in a 20.41% reduction in the ocular hypotensive effect relative to latanoprost therapy alone.
authors.affiliation: Department of Clinical Sciences, Tufts Cummings School of Veterinary Medicine, 200 Westboro Rd, North Grafton, MA 01536, USA.
authors.forename: Chris G
authors.initials: CG
authors.lastname: Pirie
authors.forename: Louise S
authors.initials: LS
authors.lastname: Maranda
authors.forename: Stefano
authors.initials: S
authors.lastname: Pizzirani
mesh_terms: D000064:Acclimatization; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology; D018592:Cross-Over Studies; D004285:Dogs; D005123:Eye / Q000187:drug effects*; D005480:Flurbiprofen / Q000008:administration & dosage* / Q000494:pharmacology*; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000494:pharmacology; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage* / Q000494:pharmacology*; D011680:Pupil / Q000187:drug effects; D013997:Time Factors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D018696:Neuroprotective Agents; D011461:Prostaglandins F, Synthetic; D005480:Flurbiprofen; D000077338:Latanoprost